Literature DB >> 27796822

Effects of Shugan Jianpi Formula () on myeloid-derived suppression cells-mediated depression breast cancer mice.

Yu-Tong Lu1,2, Jie Li3, Xin Qi1, Ying-Xia Pei1, Wen-Guang Shi1, Hong-Sheng Lin1.   

Abstract

OBJECTIVE: To observe the intervention effect of Shugan Jianpi Formula (, SGJPF) on a breast cancer mouse model with depression and investigate the underlying mechanism of SGJPF in preventing the development of breast cancer.
METHODS: The breast cancer model was induced by inoculation of breast cancer cells, the depression model was induced by chronic stress stimuli, and the depression cancer model was established by combining the two factors. The mice were divided into 7 groups: normal control, depression model, tumor model, depression tumor model, SGJPF, chemotherapy, and SGJPF+chemotherapy groups. The last 3 groups were depression breast cancer mice and treated respectively with SGJPF, chemotherapy drug gemcitabine (GEM), and SGJPF alongside GEM. The condition of the mice was evaluated by the expression of 5-hydroxytryptamine in hippocampus after the sucrose water test and open field test, weight change, and survival time. Tumor growth was monitored with in vivo imaging. Flow cytometry was used to analyze the level of myeloid-derived suppression cell (MDSC) in the mouse spleen, T cell subsets, and the early apoptosis of CD8+ T cells.
RESULTS: The SGJPF+GEM group had the highest inhibition rate and the longest survival time (P<0.01). The MDSC level and the apoptosis rate of CD8+ T cells was the highest in the SGJPF+GEM group (P<0.05).
CONCLUSIONS: Depressive disorders and tumor growth could suppress the immune function of mice to different degrees, and the microenvironment in late 4T1 inflammatory breast cancer may play an important role in the pathological process. SGJYF could regulate the immune microenvironment by reducing CD8+ T lymphocyte apoptosis and tumor cell activity, increasing immune surveillance capability, and inhibiting MDSC proliferation, thus prolonging the survival time of tumor-bearing mice.

Entities:  

Keywords:  Chinese medicine; Shugan Jianpi Formula; apoptosis; breast cancer; depressive disorders; myeloid-derived suppression cell

Mesh:

Substances:

Year:  2016        PMID: 27796822     DOI: 10.1007/s11655-016-2734-4

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  19 in total

Review 1.  Myeloid-derived suppressor cells in transplantation and cancer.

Authors:  Jordi C Ochando; Shu Hsia Chen
Journal:  Immunol Res       Date:  2012-12       Impact factor: 2.829

2.  The terminology issue for myeloid-derived suppressor cells.

Authors:  Dmitry I Gabrilovich; Vincenzo Bronte; Shu-Hsia Chen; Mario P Colombo; Augusto Ochoa; Suzanne Ostrand-Rosenberg; Hans Schreiber
Journal:  Cancer Res       Date:  2007-01-01       Impact factor: 12.701

3.  Psychiatric disorders following first breast cancer recurrence: prevalence, associated factors and relationship to quality of life.

Authors:  Masako Okamura; Shigeto Yamawaki; Tatsuo Akechi; Koji Taniguchi; Yosuke Uchitomi
Journal:  Jpn J Clin Oncol       Date:  2005-06-16       Impact factor: 3.019

4.  Chronic mild stress and depressive disorder: a useful new model?

Authors:  I Reid; N Forbes; C Stewart; K Matthews
Journal:  Psychopharmacology (Berl)       Date:  1997-12       Impact factor: 4.530

5.  The chronic mild stress depression model: future developments from a drug discovery perspective.

Authors:  J De Vry; R Schreiber
Journal:  Psychopharmacology (Berl)       Date:  1997-12       Impact factor: 4.530

6.  Polarization and reprogramming of myeloid-derived suppressor cells.

Authors:  Wen-Chin Yang; Ge Ma; Shu-Hsia Chen; Ping-Ying Pan
Journal:  J Mol Cell Biol       Date:  2013-03-25       Impact factor: 6.216

Review 7.  Role of immature myeloid cells in mechanisms of immune evasion in cancer.

Authors:  Sergei Kusmartsev; Dmitry I Gabrilovich
Journal:  Cancer Immunol Immunother       Date:  2005-07-27       Impact factor: 6.968

8.  Low brain serotonin transporter binding in major depressive disorder.

Authors:  Andrew B Newberg; Jay D Amsterdam; Nancy Wintering; Justine Shults
Journal:  Psychiatry Res       Date:  2012-06-12       Impact factor: 3.222

9.  Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts.

Authors:  Albana Cumashi; Nicola Tinari; Cosmo Rossi; Rossano Lattanzio; Clara Natoli; Mauro Piantelli; Stefano Iacobelli
Journal:  Cancer Lett       Date:  2008-06-30       Impact factor: 8.679

10.  [An observation and analysis of the features of depressive disorder in the incidence and progression of breast cancer].

Authors:  Yu-ren Zhang; Jie Li; Lei Li
Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi       Date:  2013-04
View more
  3 in total

1.  Risk of Developing Hepatocellular Carcinoma following Depressive Disorder Based on the Expression Level of Oatp2a1 and Oatp2b1.

Authors:  Yan Chen; Jiongshan Zhang; Mengting Liu; Zengcheng Zou; Fenglin Wang; Hao Hu; Baoguo Sun; Shijun Zhang
Journal:  Biomed Res Int       Date:  2019-07-29       Impact factor: 3.411

2.  The Application of Traditional Chinese Medicine Against the Tumor Immune Escape.

Authors:  Jing Xu; Jingjing Zhang; Jing Wang
Journal:  J Transl Int Med       Date:  2020-12-31

3.  Identification of Potential Diagnoses Based on Immune Infiltration and Autophagy Characteristics in Major Depressive Disorder.

Authors:  Ye Sun; Jinying Li; Lin Wang; Ting Cong; Xiuli Zhai; Liya Li; Haikuo Wu; Shouxin Li; Zhaoyang Xiao
Journal:  Front Genet       Date:  2022-04-26       Impact factor: 4.772

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.